Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Date 22 October 2018
Event ESMO 2018 Congress
Session Poster Discussion session - NETs and endocrine tumours
Topics Thyroid Cancer
Anticancer Agents
Presenter Bhumsuk Keam
Citation Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302
Authors B. Keam1, R.J. Kreitman2, Z.A. Wainberg3, M.E. Cabanillas4, D.C. Cho5, A. Italiano6, A. Stein7, J.Y. Cho8, J.H.M. Schellens9, P.Y. Wen10, C.C. Zielinski11, A.D. Boran12, B. Mookerjee13, P. Burgess14, F. Rangwala13, V. Subbiah15
  • 1Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 2Laboratory Of Molecular Biology, National Institutes of Health, Bethesda/US
  • 3Department Of Medicine, University of California Los Angeles, Los Angeles/US
  • 4Department Of Endocrine Neoplasia And Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston/US
  • 5Department Of Medicine, New York University Langone Medical Center, New York/US
  • 6Early Phase Trials And Sarcoma Units, Institute Bergonié, Bordeaux/FR
  • 7Department Of Internal Medicine Ii (oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg/DE
  • 8Department Of Medical Oncology, Yonsei University College of Medicine Gangnam Severance Hospital, Seoul/KR
  • 9Department Of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam/NL
  • 10Center For Neuro-oncology, Dana-Farber Cancer Institute, Boston/US
  • 11Department Of Medicine I, Comprehensive Cancer Center Medical University Vienna, Vienna/AT
  • 12Oncology Precision Medicine, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 13Global Clinical Program, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 14Oncology Global Development Unit, Novartis Pharma AG, Basel/CH
  • 15Department Of Investigational Cancer Therapeutics (phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston/US



ATC is a rare, aggressive malignancy with a dismal prognosis and median overall survival (OS) of < 6 mo. One-fourth of ATCs harbor activating BRAF V600E mutations. Initial data from this trial demonstrated strong efficacy of combined D (BRAF inhibitor) + T (MEK inhibitor) treatment in pts with BRAF V600–mutated ATC. Among 16 pts, overall response rate (ORR) was 69%, and median duration of response (DOR), progression-free survival (PFS), and OS were not reached (NR) due to insufficient progression and death events. D + T was recently approved by the U.S. Food and Drug Administration for the treatment of BRAF V600E-mutant ATC.


In this phase II, open-label basket trial (NCT02034110), pts with BRAF V600E mutations in 9 rare tumor types, including ATC, received continuous D (150 mg BID) + T (2 mg QD) until unacceptable toxicity or disease progression. Eligible pts had advanced or metastatic cancer with no standard-of-care treatment options. The primary endpoint was investigator-assessed ORR. Secondary endpoints included DOR, PFS, OS, and safety. We report updated data from the ATC cohort.


27 of 28 pts with ATC had evaluable data. BRAF V600E mutations were centrally confirmed in 25/28 pts. Median age was 70 y; 23/28 (82%) pts had undergone prior tumor radiation, and 13/28 pts (46%) had received ≥ 1 prior line of chemotherapy. Investigator-assessed confirmed ORR was 67% (18/27; 95% CI, 46%-84%), with 8/18 responses ongoing at data cutoff. 12/18 patients (67%) had a DOR of ≥ 6 months. Median PFS and OS were 1.2 y (95% CI, 0.4-NR) and 1.7 y (95% CI, 0.7-NR). The safety population comprised 163 pts enrolled in 8/9 histologies. Among all pts, 96% had an adverse event (AE). Common AEs of any grade for all histologies were pyrexia (50%) and fatigue (36%). In the ATC cohort, the most common grade 3/4 events were anemia (25%), hyponatremia (21%), and pneumonia (21%). Biomarker and quality-of-life analyses are ongoing and will be presented.


D + T combination therapy continues to significantly improve outcomes in ATC, with a favorable safety profile. This regimen represents a clinically meaningful therapeutic advance for pts with advanced/metastatic BRAF V600–mutated ATC.

Clinical trial identification


Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.


Novartis Pharmaceuticals Corporation.

Editorial Acknowledgement

Medical writing assistance was provided by William Fazzone, PhD (ArticulateScience LLC), funded by Novartis Pharmaceuticals Corporation.


B. Keam, A. Italiano, J.Y. Cho, J.H.M. Schellens: Assistance with abstract preparation. R.J. Kreitman: Research funding: GlaxoSmithKline (CRADA with NIH regarding research support for patients enrolled). Z.A. Wainberg: Consultancy: Novartis, Merck, EMD Serno, Lilly, Five Prime. M.E. Cabanillas: Research funding: Exelixis, Genentech, Kura; Membership on board of directors or advisory committees: Loxo, Ignyta. D.C. Cho: Consultancy: Bristol-Myers Squibb, Genentech, Exelixis, Pfizer, Prometheus. A. Stein: Research funding: German Cancer Aid, Sanofi, Roche, Merck, GBA Innovationfond, Bristol-Myers Squibb; Advisory board: Sanofi, Amgen, Merck, Roche, Bristol-Myers Squibb, MSD, Servier, Sirtex; Speakers’ fees: Sanofi, Merck, Roche, Servier, Bayer, Lilly. P.Y. Wen: Research support: AbbVie, Agios, Angiochem, Ariad, AstraZeneca, Genentech/Roche, GlaxoSmithKline, Immunocellular Therapies, Karyopharm, Merck, Novartis, Oncoceutics, Sanofi-Aventis, Vascular Biogenics; Advisory board, consulting, honoraria: AbbVie, AstraZeneca, Aurora Biopharma, Cavion, Gamestop Inc, Genentech/Roche, GW Pharmaceuticals, Immunomic Therapeutics, Insys, Kadmon, Lilly, Monteris, Novogen, Novartis, Puma, Vascular Biogenics, VBI Vaccines, Vivus, Ziopharm; Speakers' bureau: Merck. C.C. Zielinski: Honoraria: Novartis, Roche, Bristol-Myers Squibb, MSD, AstraZeneca. A.D. Boran, P. Burgess, F. Rangwala: Employment: Novartis. B. Mookerjee: Employment: Novartis; Stock ownership: Novartis, Glaxo Smith Kline, AstraZeneca. V. Subbiah: Research funding: Novartis.